BPK-S Integration (Ceramic) Post Market Clinical Follow-Up
Prospektive, Klinische Studie Zur Marktbeobachtung (Post Market Follow-Up Study) Der Knieendoprothese BPK-S Integration Aus Keramikwerkstoff BIOLOX (R) Delta (Prospective Clinical Post Market Follow-up Study of the Total Knee Endoprosthesis BPK-S (Brehm Precision Knee System)Made of Ceramic Material BIOLOX (R) Delta
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Congenital or acquired knee joint defects/deformation which necessitate the implantation of a knee joint replacement
- Defects or malfunctions of the knee joint
- Degenerative, rheumatic, post-traumatic arthritis/arthrosis
- Symptomatic knee instability
- Reconstruction of flexibility
- Patients with material hypersensitivity
Exclusion Criteria:
- Obesity or overweight of the patient
- Acute or chronic infections near the implantation
- Diseases that impair bone growth such as cancer, renal dialysis, osteopenia, etc.
- Sensitivity to foreign matter in the implant materials
- Bone tumors in the area of the implant anchoring
- Illnesses which can be treated without using a knee implant
- Lack of patient cooperation
- Abuse of medication, drug abuse, alcoholism or mental disease
- Pregnancy
- Serious osteoporosis
- Serious damage to the bone and soft tissue structures which impedes stable anchoring and joint function
- Systemic diseases and metabolic disorders
- Overload of the knee implant to be expected
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement of Knee Society Score
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement of Knee Society Score over the course of the study
Time Frame: 3 months, 24 months
|
3 months, 24 months
|
|
Improvement of EQ-5D (Euroquol 5 dimension) score
Time Frame: 3 month, 12 months, 24 months
|
3 month, 12 months, 24 months
|
|
Improvement of Oxford Score
Time Frame: 3 month, 12 months, 24 months
|
3 month, 12 months, 24 months
|
|
Documentation of Complications
Time Frame: 3 month, 12 months, 24 months
|
3 month, 12 months, 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- BPK-S-(pKK)-01-2011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restoration if Knee Joint Function
-
NCT03992443WithdrawnRestoration of Function to CVADs
-
NCT06894706CompletedFunctional Exercise Training | Knee Meniscus Injury | Knee Joint Function
-
NCT01601756UnknownRevision Total Knee Arthroplasty Because of | Loosening | Instability | Impingement | or Other Reasons Accepted as Indications for TKA Exchange. | The Focus is to Determine the Precision of Joint Line Restoration in Navigated vs. Conventional Revision Total Knee Arthroplasty
-
NCT07417033Active, not recruitingPain | Osteoarthritis | Function | Knee Joint Arthritis
-
NCT05904158CompletedEffects of Platelet-Rich Fibrin on Knee Stability and Knee Function
-
NCT01379118CompletedPain | Osteoarthritis | Degenerative Joint Disease | Connective Tissue Disorder | Knee Injury, Trauma | Loss of Function
-
NCT05279573CompletedJoint Function Disorder
-
NCT03949400RecruitingPain | Osteoarthritis, Knee | Rehabilitation | Patient Reported Outcome Measures | Adults | Recovery of Function | Treatment Outcome | Knee Brace | Outcome Assessment (Health Care)
-
NCT02845960UnknownArthritis, Rheumatoid | Arthroplasty, Replacement, Knee | Recovery of Function
-
NCT07267793RecruitingOsteoarthritis | Knee Osteoarthritis | Degenerative Joint Disease of Knee | Cartilage Defects of the Knee | Knee Pain Arthritis
Clinical Trials on BPK-S Integration (Ceramic)
-
NCT02615522TerminatedOsteoarthritis, Knee | Joint Instability
-
NCT03406637CompletedOsteoarthritis, Knee | Joint Instability
-
NCT03293719TerminatedArthritis | Rheumatic Diseases | Osteoarthritis | Osteoarthritis, Knee | Joint Instability | Musculoskeletal Disease | Joint Disease
-
NCT02535312Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Unresectable Solid Neoplasm | Advanced Pleural Malignant Mesothelioma | Advanced Peritoneal Malignant Mesothelioma
-
NCT02561273CompletedAnaplastic Large Cell Lymphoma, ALK-Positive | Hepatosplenic T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic Large Cell Lymphoma, ALK-Negative | Stage II Angioimmunoblastic T-cell Lymphoma | Stage II Enteropathy-Associated T-Cell Lymphoma | Stage III Angioimmunoblastic T-cell Lymphoma | Stage III Enteropathy-Associated T-Cell Lymphoma | Stage IV Angioimmunoblastic T-cell Lymphoma | Stage IV Enteropathy-Associated T-Cell Lymphoma